Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 3/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951311 | 1.00 | KIF11 (0.51) | KIF11CYP2A6TTKHDAC1KDM4E | |
| SCHEMBL2628327 | 0.76 | KDM4E (0.55) | KIF11KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL6299735 | 0.76 | KIF11 (0.81) | KIF11CYP2A6KDM4EALDH1A1MAPT | |
| SCHEMBL6925164 | 0.75 | KIF11 (0.63) | KIF11TTKKDM4EALDH1A1CHUK | |
| SCHEMBL29669815 | 0.75 | KDM4E (0.48) | KIF11KDM4EALDH1A1MAPTPOLB | |
| SCHEMBL6826347 | 0.74 | GABRA1 (0.58) | KIF11ALDH1A1MAPTPOLB | |
| SCHEMBL30961885 | 0.74 | KDM4E (0.63) | KIF11KDM4EALDH1A1MAPTMAPK1 | |
| SCHEMBL31219220 | 0.73 | CHUK (0.60) | KDM4EALDH1A1MAPTCHUKPOLB | |
| Benzene SCHEMBL28184721 | 0.73 | KIF11 (0.81) | KIF11CYP2A6TTKKDM4EALDH1A1 | |
| SCHEMBL2391060 | 0.72 | GABRA1 (0.53) | KDM4EALDH1A1MAPK1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | SUGEN, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6514981-B1 | By contacting cells expressing said protein tyrosine kinase with compound | SUGEN, INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203901-A1 | Methods of modulating tyrosine protein kinase function with indolinone compounds | LCK, ABL1, PNCK | KIF11 3404/4885CYP2A6 4366/4885TTK 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.